MARKET

ARWR

ARWR

Arrowhead Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

57.02
-3.37
-5.58%
After Hours: 57.02 0 0.00% 19:58 11/25 EST
OPEN
60.17
PREV CLOSE
60.39
HIGH
60.17
LOW
56.05
VOLUME
1.95M
TURNOVER
--
52 WEEK HIGH
73.72
52 WEEK LOW
19.51
MARKET CAP
5.86B
P/E (TTM)
-237.1880
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda
Business Wire · 1d ago
Sundial Growers, DiaMedica Therapeutics leads healthcare gainers; Medigus, Graybug Vision among major losers
Gainers: Sundial Growers (SNDL) +36%, DiaMedica Therapeutics (DMAC) +20%, Aurora Cannabis (ACB) +19%, Lyra Therapeutics (LYRA) +19%, Tilray (TLRY) +10%.Losers: Medigus (MDGS) -17%, Graybug Vision (GRAY) -14%, Immunic (IMUX) -13%, Arrowhead Pharmaceuticals (ARWR) -12%, Seres Therapeutics (MCRB) -10%.
Seekingalpha · 2d ago
The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 23)
Benzinga · 2d ago
Recap: Arrowhead Pharmaceuticals Q4 Earnings
Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) decreased 2.49% in after-market trading after the company reported Q4 results.Quarterly Results Earnings per share decreased 536.36% over the past year to ($0.48), which missed the estimate of $0.12.Revenue of $7,632,000 decreased by 82.37% from the same period last year, which missed the estimate of $49,240,000.Guidance Earnings guidance hasn't been issued by the company for now.Arrowhead Pharmaceuticals hasn't issued any revenue guidance for the time being.How To Listen To The Conference Call Date: Nov 23, 2020View more earnings on ARWRTime: 04:30 PMET Webcast URL: https://edge.media-server.com/mmc/p/xqpf829iTechnicals Company's 52-week high was at $73.7252-week low: $19.51Price action over last quarter: Up 63.33%Company Profile Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.See more from Benzinga * Click here for options trades from Benzinga * 12 Healthcare Stocks Moving In Monday's After-Market Session * Earnings Scheduled For November 23, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 2d ago
Arrowhead Pharmaceuticals EPS of -$0.84
Arrowhead Pharmaceuticals (ARWR): FY EPS of -$0.84 may not be comparable to consensus of -$0.23.Revenue of $87.99M (-47.9% Y/Y) misses by $46.62M.Press Release
Seekingalpha · 2d ago
Arrowhead Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 23, 2020 / Arrowhead Pharmaceuticals, Inc.
ACCESSWIRE · 3d ago
The Week Ahead In Biotech: Moderna Vaccine And Roche, Revance, Rhythm, Liquidia FDA Updates
Biotech stocks came under pressure in the week ended Nov. 20, reversing course from the previous week.
Benzinga · 4d ago
Citigroup Initiates Coverage On Arrowhead Pharmaceuticals with Buy Rating, Announces Price Target of $90
Citigroup analyst Shawn Egan initiates coverage on Arrowhead Pharmaceuticals (NASDAQ:ARWR) with a Buy rating and announces Price Target of $90.
Benzinga · 11/19 12:46
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ARWR. Analyze the recent business situations of Arrowhead Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ARWR stock price target is 75.09 with a high estimate of 98.00 and a low estimate of 34.00.
EPS
Institutional Holdings
Institutions: 422
Institutional Holdings: 78.08M
% Owned: 75.99%
Shares Outstanding: 102.76M
TypeInstitutionsShares
Increased
78
3.71M
New
65
941.79K
Decreased
93
5.14M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.74%
Pharmaceuticals & Medical Research
+0.82%
Key Executives
Chairman/Director
Douglass Given
Chief Executive Officer/President/Director
Christopher Anzalone
Chief Financial Officer
Kenneth Myszkowski
Chief Scientific Officer
Curt Bradshaw
General Counsel
Patrick O'Brien
Other
James Hassard
Other
Javier San Martin
Lead Director/Independent Director
Michael Perry
Independent Director
Marianne De Backer
Independent Director
Mauro Ferrari
Independent Director
Oye Olukotun
Independent Director
William Waddill
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ARWR
Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Arrowhead Pharmaceuticals Inc stock information, including NASDAQ:ARWR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARWR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARWR stock methods without spending real money on the virtual paper trading platform.